| Published time |
Research type |
Research object |
Follow-up time |
Treatment |
Outcome |
| 1999 [9] |
Prospective cohort study |
86 IgAN; urine protein 1.0 - 3.5 g/d, SCr ≤133 μmol/L (1.5 mg/dL) |
5 years |
Supportive therapy alone or steroid treatment (IV MP 1 gX3 d at the beginning of months 1, 3, and 5, plus oral prednisone 0.5 mg/kg on alternate days for 6 months |
20.9% in the steroid group and 32.6% in the control group reached the primary endpoint* (p<0.048) |
| 2008 [14] |
Retrospective cohort study |
702 IgAN patients |
Median 5.1 years |
Oral steroids (n=194), MP pulse therapy followed by oral prednisolone (n=34), 474 patients with no steroid |
Steroid pulse therapy significantly decreased the risk of ESRF while oral steroid treatment did not improve renal survival |
| 2009 [10] |
Prospective cohort study |
63 IgAN patients with proteinuria of 1 to 5 g/d. |
4 years |
Cilazapril alone (ACEI group; n=30) or steroid plus cilazapril (combination group; n=33) |
24.1% in the ACEI group and 3% in the combination group reached the primary end point*. Urine protein excretion significantly decreased in patients in the combination group |
| 2009 [11] |
Prospective cohort study |
97 IgAN patients with moderate histologic lesions, proteinuria ≥1.0 g/d; GFR≥50 ml/min |
8 years |
6-month course of oral prednisone plus ramipril (combination therapy group) or ramipril alone (monotherapy group) |
26.5% in the monotherapy group reached the primary outcome** compared with 4.2% in the combination therapy group. The combined treatment reduced 24-h proteinuria more than ramipril alone during the first 2 years |
| 2012 [15] |
observational study |
22 active IgAN (median histological Grade 3) patients with CKD Stage 3 - 5; median eGFR 34.05 ml/min |
Not known |
Treated with 500 mg intravenous MP every 2 weeks for 6 months. All patients had been maintained on an ACEI or ARB |
73% had improvements in the monthly decline of eGFR. The rate of eGFR decline in the before treatment period differed significantly from that in the after treatment period |
Methylprednisolone: MP; * A 50% increase in baseline serum creatinine level.